Short-term costs associated with primary prophylactic G-CSF use during chemotherapy

American Journal of Managed Care

Volumn 19, Issue 2, 2013, Pages 150-159

  Rajan, Suja S ^a   Carpenter, William R ^b   Stearns, Sally C ^b   Lyman, Gary H ^c  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b University of North Carolina at Chapel Hill   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR;

ARTICLE; CANCER CHEMOTHERAPY; COST CONTROL; HOSPITALIZATION COST; HUMAN; MEDICARE; NEUTROPENIA; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIMARY PREVENTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

AGED; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HOSPITAL COSTS; HUMANS; NEUTROPENIA; REGISTRIES; RETROSPECTIVE STUDIES; SEER PROGRAM; UNITED STATES;

EID: 84875179981     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Earle CC, Nattinger AB, Potosky AL, et al. Identifying cancer relapse using SEER-Medicare Data. Med Care. 2002;40(8) (suppl):IV-104-IV-117.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;365(9472):1687-1717.
3. Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet. 1998;352(9132):930-942.
4. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomised trials among 28, 896 women. Early Breast Cancer Trialists' Collaborative Group. N Engl J Med. 1992;319(26):1681-1692.
5. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Systemic Treatment of Early Breast Cancer by Hormonal, Cytotoxic, or Immune Therapy: 133 Randomised Trials Involving 31, 000 Recurrences and 24, 000 Deaths Among 75, 000 Women. Lancet. 1988;339(8785):1-15, 71-85.
6. Fisher B. Highlights from recent National Surgical Adjuvant Breast and Bowel Project studies in the treatment and prevention of breast cancer. CA Cancer J Clin. 1999;49(3):159-177. (Pubitemid 29353929)
7. Fisher B, Redmond C, Legault-Poisson S, et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol. 1990;8(6):1005-1018. (Pubitemid 20200188)
8. Hortobagyi GN. Treatment of breast cancer. N Engl J Med. 1998;339(14):974-984. (Pubitemid 28455101)
9. Shayne M, Crawford J, Dale DC, Culakova E, Lyman GH; ANC Study Group. Predictors of reduced dose intensity in patients with earlystage breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat. 2006;100(3):255-262. (Pubitemid 44707919)
10. Ziegler J, Citron M. Dose-dense adjuvant chemotherapy for breast cancer. Cancer Nurs. 2006;29(4):266-272. (Pubitemid 44181538)
11. Chrischilles EA, Link KB, Scott SD, Delgado DJ, Fridman M. Factors associated with early termination of CHOP therapy and the impact on survival among patients with chemosensitive intermediate grade non-Hodgkin's lymphoma. Cancer Control. 2003;10(5):396-403. (Pubitemid 37296067)
12. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dosedense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21(8):1431-1439. (Pubitemid 46594092)
13. Bonilla L, Ben-Aharon I, Vidal L, Gafter-Gvili A, Leibovici L, Stemmer SM. Dose-dense chemotherapy in nonmetastatic breast cancer: A systematic review and meta-analysis of randomized controlled trials. J Natl Cancer Inst. 2010;102(24):1845-1854.
14. Ozer H, Armitage JO, Bennett CL, et al; American Society of Clinical Oncology. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of C linical Oncology Growth Factors Expert Panel. J C lin Oncol. 2000;18(20):3558-3585.
15. Baquiran DC. Biologic response modifiers. In: Baquiran DC, ed. Lippincott's Cancer Chemotherapy Handbook. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:13-41.
16. Webster J, Lyman G. Use of G-CSF to sustain dose intensity in breast cancer patients receiving adjuvant chemotherapy: a pilot study. Cancer Control. 1996;3(6):519-523. (Pubitemid 27062011)
17. Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G. Filgrastim (r-metHuG-CSF): the first 10 years. Blood. 1996;88(6):1907-1929. (Pubitemid 26307891)
18. Hryniuk WM. The importance of dose intensity in the outcome of chemotherapy. In: De Vita VT, Hellman S, Rosenberg SA, eds. Important Advances in Oncology. Philadelphia, PA: JB Lippincott; 1988:121-141.
19. Budman DR, Berry DA, Cirrincion CT, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst. 1998;90(16):1205-1211. (Pubitemid 28407086)
20. Lyman GH, Kuderer N, Agboola O, Balducci L. Evidence-based use of colony-stimulating factors in elderly cancer patients. Cancer Control. 2003;10(6):487-499. (Pubitemid 37493953)
21. Lyman GH, Kuderer NM, Greene J, Balducci L. The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer. 1998;34(12):1857-1864. (Pubitemid 28535432)
22. Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25(21):3158-3167. (Pubitemid 47218066)
23. Lyman GH, Kuderer NM, Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med. 2002;112(5):406-411. (Pubitemid 34246271)
24. Rajan SS, Lyman GH, Stearns SC, Carpenter WR. Effect of primary prophylactic granulocyte colony-stimulating factor use on incidence of neutropenia hospitalizations for elderly early-stage breast cancer patients receiving chemotherapy. Med Care. 2011;49(7):649-657.
25. Caggiano V, Weiss RV, Richert TS, Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005;103(9):1916-1924. (Pubitemid 40563265)
26. Eldar-Lissai A, Cosler LE, Culakova E, Lyman GH. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health. 2007;11(2):172-179.
27. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Morbidity, mortality and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106(10):2258-2266. (Pubitemid 43673249)
28. Weycker D, Malin J, Glass A, Oster G. Economic burden of chemotherapy-related febrile neutropenia. J Support Oncol. 2007;5(4) (suppl 2):44-45.
29. Weycker D, Malin J, Glass A, Oster G. Cost of chemotherapy-related febrile neutropenia [abstract]. J Clin Oncol. 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2006;24(18S) (June 20 suppl). http://meeting.ascopubs.org/cgi/content/abstract/24/18-suppl/6068. Published June 2006. Accessed January 11, 2013.
30. Weycker D, Hackett J, Edelsberg JS, Oster G, Glass AG. Duration of G-CSF therapy and risk of hospitalization for neutropenia or infection [abstract 6731]. J Clin Oncol. 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2004;22(14S) (July 15 suppl).
31. Lyman GH, Lyman CG, Sanderson RA, Balducci L. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst. 1993;85(6):488-493. (Pubitemid 23084095)
32. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991;325(3):164-170.
33. Chrischilles E, Delgado DJ, Stolshek BS, Lawless G, Fridman M, Carter WB. Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated Non-Hodgkin's lymphoma. Cancer Control. 2002;9(3):203-211. (Pubitemid 34657282)
34. Glaspy JA, Bleecker G, Crawford J, Stoller R, Strauss M. The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy. Eur J Cancer. 1993;29A(suppl 7):S23-S30. (Pubitemid 24037726)
35. Zagonel V, Babare R, Merola MC, et al. Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy. Ann Oncol. 1994;5(suppl 2) 127-132. (Pubitemid 24061335)
36. Uyl-de Groot CA, Vellenga E, Rutten FF. An economic model to assess the savings from a clinical application of hematopoietic growth factors. Eur J Cancer. 1996;32A(1):57-62.
37. Dranitsaris G, Sutcliffe SB. Economic analysis of prophylactic G-CSF after mini-BEAM salvage chemotherapy for Hodgkin's and non-Hodgkin's lymphoma. Leuk Lymphoma. 1995;17(1-2):139-145.
38. Bassan R, Lerede T, Di Bona E, et al. Granulocyte colony-stimulating factor (G-CSF, filgrastim) after or during an intensive remission induction therapy for adult acute lymphoblastic leukaemia: effects, role of patient pretreatment characteristics, and costs. Leuk Lymphoma. 1997;26(1-2):153-161. (Pubitemid 27351019)
39. Hassett MJ, O'Malley AJ, Pakes JR, Newhouse JP, Earle CC. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst. 2006;98(16):1108-1117. (Pubitemid 44288785)
40. Russo A, Autelitano M, Bisanti L. Re: frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst. 2006;98(24):1826-1827. (Pubitemid 46017936)
41. Du XL, Osborne C, Goodwin JS. Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol. 2002;20(24):4636-4642. (Pubitemid 36025279)
42. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24(19):3187-3205. (Pubitemid 46638957)
43. Neupogen (Filgrastim) [package insert]. Thousand Oaks, CA: Amgen; 2009.
44. Weycker D, Hackett J, Edelsberg JS, Oster G, Glass AG. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother. 2006;40(3):402-407.
45. Scott SD, Chrischilles EA, Link BK, et al. Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapy. J Manag Care Pharm. 2003;9(2 suppl):15-21.
46. Warren JL, Klabunde CN, Schrag Deborah, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8) (suppl):IV-3-IV-18.
47. Perry MC, Yarbro JW. Toxicity of Chemotherapy. Orlando, FL: Grune & Stratton; 1984.
48. Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med. 2001;344(26):1997-2008. (Pubitemid 32568155)
49. Crawford J, Kreisman H, Garewal H, et al. The impact of filgrastim schedule variation on hematopoietic recovery post-chemotherapy. Ann Oncol. 1997;8(11):1117-1124. (Pubitemid 27521219)
50. National Comprehensive Cancer Network. Myeloid Growth Factors. NCCN Guidelines for Supportive Care. http://www.nccn.org/professionals/physician-gls/ f-guidelines.asp#supportive. Published 2010. Accessed December 2011.
51. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 2003;21(24):4524-4531. (Pubitemid 46594022)
52. Gómez H, Hidalgo M, Casanova L, et al. Risk factors for treatmentrelated death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis. J Clin Oncol. 1998;16(6):2065- 2069. (Pubitemid 28265042)
53. Du XL, Lairson DR, Begley E, Fang S. Temporal and geographic variation in the use of hematopoietic growth factors in older women receiving breast cancer chemotherapy: findings from a large population-based cohort. J Clin Oncol. 2005;23(34):8620-8628. (Pubitemid 46211504)
54. Lyman GH. Risk assessment in oncology clinical practice: from risk factors to risk models. Oncology (Williston Park). 2003;17(11) (suppl 11):8-13.
55. Lyman GH, Kuderer NM. Economics of hematopoietic growth factors. In: Morstyn G, Foote M, Lieschke GJ, eds. Hematopoietic Growth Factors in Oncology: Basic Science and Clinical Therapeutics. Totowa, NJ: Humana Press Inc; 2004:409-443.
56. Rajan SS, Lyman GH, Carpenter WR, Stearns SC. Chemotherapy characteristics are important predictors of primary prophylactic CSF administration in older patients with breast cancer. Breast Cancer Res Treat. 2011;127(2):511-520.
57. Rajan SS, Stearns SC, Lyman GH, Carpenter WR. Effect of primary prophylactic G-CSF use on systemic therapy administration for elderly breast cancer patients. Breast Cancer Res Treat. 2011;130(1):255-266.
58. Ho DE, Imai IK, King G, Stuart EA. Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference. Polit Anal. 2007;15:199-236.
59. King G, Zeng L. The dangers of extreme counterfactuals. Polit Anal. 2006;14:131-159. (Pubitemid 43444515)
60. Robins J, Rotnitzky A. Comment on "Inference for semiparametric models: some questions and an answer" by P. J. Bickel and J. Kwon. Statistica Sinica. 2001;11:920-936.
61. Sekhon JS, Mebane WRJ. Genetic optimization using derivatives: theory and application to nonlinear models. Polit Anal. 1998;7(1):187-210.
62. Diamond A, Sekhon J. Genetic matching for estimating causal effects: a genetic multivariate matching method for achieving balance in observational studies. Rev Econ Stat. In press.
63. Gandhi SK, Arguelles L, Boyer JG. Economic impact of neutropenia and febrile neutropenia in breast cancer: estimates from two national databases. Pharmacotherapy. 2001;21(6):684-690. (Pubitemid 32506484)
64. Brooks JM, Klepser DG, Chrischilles EA, Voelker MD, Chen-Hardee SS, Scott SD, Link BK, Delgado DJ. Early termination of first course chemotherapy among Medicare beneficiaries newly diagnosed with non-Hodgkin's lymphoma: National SEER-Medicare study. Proc Am J Clin Oncol. 2003;22:(abstr 2145).
65. Chrischilles EA, Klesper DG, Brooks JM, et al. Effect of clinical characteristics on neutropenia-related inpatient costs among newly diagnosed non-Hodgkin's lymphoma cases during first course chemotherapy. Pharmacotherapy. 2005;25(5):668-675. (Pubitemid 40604882)